[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Colombat P, Cornillet P, Deconinck E, Tourani JM, Gardembas M, Delain M, Abgrall JF, Kootz C, Milpied N: Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Bone Marrow Transplant; 2000 Nov;26(9):971-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
  • This prospective phase II study was undertaken to evaluate the efficacy and toxicity of early intensive therapy followed by purged autologous bone marrow transplantation (ABMT) in patients with follicular lymphoma with high tumor burden.
  • All patients received the VCAP regimen (vindesine, cyclophosphamide, doxorubicin and prednisone) as conventional chemotherapy and DHAP as second-line therapy.
  • Preparative therapy consisted of cyclophosphamide and total body irradiation (TBI) in all the patients.
  • Two treatment-related early deaths were observed.
  • These encouraging results lay the basis of future prospective randomized trials comparing autologous stem cell transplantation as front-line treatment with conventional chemotherapy for patients with bad prognostic factors.
  • [MeSH-major] Bone Marrow Purging. Hematopoietic Stem Cell Transplantation. Lymphoma, Follicular / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Genes, Immunoglobulin. Genes, bcl-2. Humans. Lung Diseases, Interstitial / etiology. Male. Middle Aged. Neoplasm, Residual. Neutropenia / etiology. Polymerase Chain Reaction. Prednisone / administration & dosage. Prednisone / adverse effects. Recurrence. Remission Induction. Sepsis / etiology. Survival Analysis. Thrombocytopenia / etiology. Translocation, Genetic. Transplantation Conditioning / adverse effects. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11100276.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; CHOP protocol; DHAP protocol
  •  go-up   go-down


2. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
  • PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype.
  • PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.
  • RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).
  • Acute nonlymphocytic leukemia risks were significantly elevated after FL and DLBCL, particularly among patients receiving initial chemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Diff) < .001).
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).
  • CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk.
  • Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


3. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, Klein J, Halpern W, Miceli R, Kumm E, Fox NL, Czuczman MS: A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer; 2010 Dec 7;103(12):1783-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.
  • BACKGROUND: we conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with relapsed non-Hodgkin's lymphoma (NHL).
  • RESULTS: mapatumumab was well tolerated, with no patients experiencing drug-related hepatic or other dose-limiting toxicity.
  • Three patients with follicular lymphoma (FL) experienced clinical responses, including two with a complete response and one with a partial response.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Receptors, TNF-Related Apoptosis-Inducing Ligand / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Cancer Resaerch UK.
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Br J Cancer. 2010 Feb 2;102(3):506-12 [20068564.001]
  • [Cites] J Pathol. 2003 Jul;200(3):327-35 [12845629.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):618-24 [9401075.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1430-41 [15846298.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):501-10 [16098063.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1346-52 [16638930.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1390-5 [17416859.001]
  • [Cites] J Urol. 2007 May;177(5):1894-9 [17437844.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4556-64 [17671142.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5528s-5534s [17875785.001]
  • [Cites] Adv Exp Med Biol. 2008;615:127-58 [18437894.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3450-5 [18519776.001]
  • [Cites] Lung Cancer. 2008 Jul;61(1):82-90 [18255187.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5584-90 [19690193.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3058-65 [11698291.001]
  • (PMID = 21081929.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / mapatumumab
  • [Other-IDs] NLM/ PMC3008610
  •  go-up   go-down


Advertisement
4. Zinzani PL: Salvage chemotherapy in follicular non-Hodgkin's lymphoma: focus on tolerability. Clin Lymphoma Myeloma; 2006 Sep;7(2):115-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy in follicular non-Hodgkin's lymphoma: focus on tolerability.
  • Follicular lymphoma (FL) is typically characterized by repeated remissions and relapses, and many patients receive a number of therapeutic interventions during their disease course.
  • Although treatment options are evolving rapidly, stem cell transplantation offers a potentially favorable impact on survival.
  • Salvage chemotherapy consequently remains the mainstay of treatment, being individualized according to disease and patient characteristics, goals of therapy, and patient preference.
  • Acute myeloid leukemias, myelodysplastic syndromes, or solid tumors can occur after chemotherapy with alkylating agents.
  • The cardiotoxic profile of anthracycline antibiotics is well recognized, and several agents, including carmustine and cyclophosphamide, can cause lung injury.
  • Novel therapeutic strategies might allow patients to achieve longer remissions, potentially reducing lifetime exposure to repeated cycles of chemotherapy and their attendant toxicities.
  • These could include the use of more efficient preparative and purging approaches in the transplantation setting or the administration of rituximab maintenance therapy after (immuno) chemotherapy induction or transplantation.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Lymphoma, Follicular / complications. Lymphoma, Follicular / therapy. Salvage Therapy
  • [MeSH-minor] Age Factors. Comorbidity. Disease-Free Survival. Humans. Remission Induction. Stem Cell Transplantation / methods. Time Factors

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026822.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 94
  •  go-up   go-down


5. Cannizzo E, Sohani AR, Ferry JA, Hochberg EP, Kluk MJ, Dorn ME, Sadowski C, Bucci JJ, Ackerman AM, Longtine JA, Carulli G, Preffer FI: Carcinoma and multiple lymphomas in one patient: establishing the diagnoses and analyzing risk factors. J Hematop; 2009;2(3):163-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a patient who showed the sequential occurrence of four different lymphoid neoplasms together with a squamous cell carcinoma of the lung.
  • A 62-year-old man with adenopathy was admitted to the hospital, and lymph node biopsy was positive for low-grade follicular lymphoma.
  • He achieved a partial remission with chemotherapy.
  • Two years later, a PET-CT scan showed a left hilar mass in the lung; biopsy showed a squamous cell carcinoma.
  • Simultaneously, he was diagnosed with diffuse large B cell lymphoma in a neck lymph node; after chemo- and radiotherapy, he achieved a complete response.
  • A restaging PET-CT scan 2 years later revealed a retroperitoneal nodule, and biopsy again showed a low-grade follicular lymphoma, while a biopsy of a cutaneous scalp lesion showed a CD30-positive peripheral T cell lymphoma.
  • After some months, a liver biopsy and a right cervical lymph node biopsy showed a CD30-positive peripheral T cell lymphoma consistent with anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
  • Flow cytometry and cytogenetic and molecular genetic analysis performed at diagnosis and during the patient's follow-up confirmed the presence of two clonally distinct B cell lymphomas, while the two T cell neoplasms were confirmed to be clonally related.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2002 Nov;100(5 Pt 2):1079-82 [12423812.001]
  • [Cites] J Chemother. 2003 Aug;15(4):406-8 [12962371.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1489-97 [17372278.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):630-6 [11979093.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Jun;17(2):239-42 [9700587.001]
  • [Cites] Leuk Lymphoma. 1999 Mar;33(1-2):161-8 [10194134.001]
  • [Cites] Eur J Haematol. 2000 Aug;65(2):123-7 [10966173.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):997-1005 [11592772.001]
  • [Cites] Rinsho Ketsueki. 1986 Dec;27(12):2313-8 [3573322.001]
  • (PMID = 20309424.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2766444
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Cytogenetics / Diffuse large B cell lymphoma / Follicular lymphoma / Multiple malignancies / Risk factors
  •  go-up   go-down


6. Lee Y, Kyung SY, Choi SJ, Bang SM, Jeong SH, Shin DB, Lee JH: Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med; 2006 Sep;21(3):183-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of interstitial pneumonitis caused by rituximab therapy.
  • Rituximab, a chimeric monoclonal antibody directed against CD20, has become a part of the standard therapy for patients with non-Hodgkin's lymphoma either in combination with other drugs or as a single agent.
  • The CD20 antigen is expressed on 95% of B-cell lymphoma cells and normal B-cells but, is not found on precursor B-cells or stem cells.
  • Rituximab is now approved for patients with diffuse large B-cell lymphoma when combined with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) or patients with follicular lymphoma who have failed first line chemotherapy.
  • Here, we report two patients with non-Hodgkin's lymphoma in whom interstitial pneumonitis developed with rituximab therapy.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / adverse effects. Lung Diseases, Interstitial / chemically induced
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Humans. Male. Methylprednisolone / therapeutic use. Prednisolone / therapeutic use. Rituximab

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Hematol J. 2001;2(6):378-84 [11920277.001]
  • [Cites] Chest. 2002 Dec;122(6 Suppl):334S-339S [12475811.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):520-35 [12649096.001]
  • [Cites] Int J Hematol. 2005 Feb;81(2):169-70 [15765788.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2690-1; discussion 2690-1 [12826649.001]
  • [Cites] Mayo Clin Proc. 2004 Jul;79(7):949, 953 [15244399.001]
  • [Cites] Am J Hematol. 2004 Sep;77(1):103-4 [15307117.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4711-6 [15483015.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):694-704 [15681517.001]
  • [Cites] Chest. 2003 Jun;123(6):2007-11 [12796182.001]
  • (PMID = 17017668.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 9PHQ9Y1OLM / Prednisolone; X4W7ZR7023 / Methylprednisolone
  • [Other-IDs] NLM/ PMC3890722
  •  go-up   go-down


7. Tímár J, Kásler M, Kátai J, Soós M, Mathiasz D, Romány A, Patthy L, Kovács G, Józsa A, Szilák L, Forrai T: [Developments in cancer management by innovative genomics. 2006 report of the National Cancer Consortium]. Magy Onkol; 2006;50(4):349-59
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Molecular diagnostic tool was established to monitor the progression of follicular lymphoma using Bcl-2/IgH fusion sequences.
  • Molecular diagnostic tools were developed to monitor circulating endothelial precursor cells (CEP) as well and the technique was tested in lung cancer patients.
  • In malignant melanoma we have tested several potential novel markers among which ryanodine receptor seems to be a promising one, while the functional P2X7 receptor may serve as a therapeutic target.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Biomarkers, Tumor / genetics. Genomics. Mutation. Neoplasms / diagnosis. Neoplasms / genetics
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Disease Progression. Female. Glycine Hydroxymethyltransferase / genetics. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / genetics. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Male. Melanoma / diagnosis. Melanoma / genetics. Neovascularization, Pathologic / diagnosis. Neovascularization, Pathologic / drug therapy. Pharmacogenetics. Polymorphism, Genetic. Prognosis. Receptors, Purinergic P2 / drug effects. Receptors, Purinergic P2X7. Ryanodine Receptor Calcium Release Channel / drug effects. Testicular Neoplasms / diagnosis. Testicular Neoplasms / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17216011.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / P2RX7 protein, human; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X7; 0 / Ryanodine Receptor Calcium Release Channel; EC 2.1.2.1 / Glycine Hydroxymethyltransferase
  • [Number-of-references] 15
  •  go-up   go-down


8. Sakai M, Bandobashi K, Ikezoe T, Kubota T, Yokoyama A: [A case of sarcoidosis following chemotherapy for follicular lymphoma]. Nihon Kokyuki Gakkai Zasshi; 2010 Oct;48(10):774-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sarcoidosis following chemotherapy for follicular lymphoma].
  • A 53-year-old man, who had received salvage chemotherapy for follicular lymphoma, complained of fever and dry cough.
  • High-resolution computed tomography of the chest showed bilateral diffuse ground-glass opacities with weak F18-fluorodeoxyglucose uptake on positron emission tomography.
  • Transbronchial lung biopsy specimens revealed noncaseating epithelioid cell granulomas.
  • [MeSH-major] Lymphoma, Follicular / complications. Sarcoidosis / etiology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21066868.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


9. Stacy RC, Jakobiec FA, Schoenfield L, Singh AD: Unifocal and multifocal reactive lymphoid hyperplasia vs follicular lymphoma of the ocular adnexa. Am J Ophthalmol; 2010 Sep;150(3):412-426.e1
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unifocal and multifocal reactive lymphoid hyperplasia vs follicular lymphoma of the ocular adnexa.
  • PURPOSE: To characterize the differentiating histopathologic and immunophenotypic features of reactive lymphoid hyperplasia (RLH) and follicular lymphoma of the ocular adnexa.
  • METHODS: Clinical records of 9 cases of RLH and 6 cases of follicular lymphoma from 2 institutions were reviewed.
  • RESULTS: RLH preferentially involved the conjunctiva, whereas follicular lymphoma had a propensity to involve the lacrimal gland.
  • Microscopic analysis with immunohistochemical staining distinguished RLH from follicular lymphoma.
  • BCL-2 was positive in follicular centers of follicular lymphoma but not in RLH.
  • CD10 identified follicular center cells and Ki67 quantified cells in S-phase.
  • None of the patients with RLH developed lymphoma during their clinical courses (up to 18 years).
  • However, 3 patients with orbital, but not conjunctival, RLH developed immunohistochemically proven multifocal nonophthalmic supradiaphragmatic adnexal RLH (sites included lung, parotid, axillary nodes, and uvea).
  • All 6 patients with follicular lymphoma had disseminated disease.
  • CONCLUSIONS: A correct diagnosis of RLH vs follicular lymphoma can be reliably established employing immunohistochemical methods.
  • A heretofore undescribed "multifocal RLH" syndrome must be distinguished from follicular lymphoma.
  • Conjunctival RLH can usually be managed surgically without radiotherapy, but "multifocal RLH" required systemic treatment in 2 of 3 patients.
  • Follicular lymphoma requires systemic chemotherapy if discovered beyond stage 1E.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Conjunctival Neoplasms / diagnosis. Lymphoma, Follicular / diagnosis. Neoplasm Proteins / metabolism. Orbital Neoplasms / diagnosis. Pseudolymphoma / diagnosis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • [ErratumIn] Am J Ophthalmol. 2010 Dec;159(6):943
  • (PMID = 20599186.001).
  • [ISSN] 1879-1891
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


10. Glimelius B, Bergh J, Brandt L, Brorsson B, Gunnars B, Hafström L, Haglund U, Högberg T, Janunger KG, Jönsson PE, Karlsson G, Kimby E, Lamnevik G, Nilsson S, Permert J, Ragnhammar P, Sörenson S, Nygren P: The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions. Acta Oncol; 2001;40(2-3):135-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.
  • This report by The Swedish Council on Technology Assessment in Health Care (SBU) reviews, classifies, and grades the scientific literature on cancer chemotherapy in some major tumour types, describes the practice of chemotherapy in Sweden, compares practice with scientific knowledge, and analyses the costs and cost-effectiveness of chemotherapy.
  • The report is intended primarily for decision-makers at various levels, both practitioners and administrators.
  • For the final evaluation to be as close to the objective truth as possible, a concerted effort was made to guarantee objectivity and thorough assessment of current knowledge about the effects of chemotherapy on the selected cancers.
  • The tumour types selected for this assessment include firstly those types where three investigations had shown an increased use of chemotherapy in Sweden during the latest decade.
  • These were non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, colorectal cancer and urinary bladder cancer.
  • Secondly, the two tumour types comprising the greatest number of patients treated with chemotherapy in Sweden, breast cancer and haematological malignancies, were included.
  • Among the haematological malignancies, the most prevalent ones, acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), Hodgkin's disease (HD), aggressive non-Hodgkin's lymphoma (NHL) of the large B-cell type and indolent NHL of follicular type were evaluated.
  • Thirdly, ovarian cancer was included since chemotherapy has been extensively used and since, at the time of the planning of this overview, a group of very expensive drugs, the taxanes, had preliminarily shown promising results.
  • A wealth of scientific literature has been published on cancer therapy.
  • The review presented in this report is limited to scientific studies judged to be important for evaluating chemotherapy efficacy.
  • The survey of practice of chemotherapy use involved all departments of surgery, urology, gynaecology, internal medicine including haematologic units, pulmonary medicine and general and gynaecologic oncology at 16 hospitals in two health care regions in Sweden, covering 39% of the Swedish population.
  • During the 4 weeks of the survey, all patients with the diagnoses concerned who received chemotherapy were registered.
  • The working group's general conclusions are summarised in the following points: The literature on the effects of chemotherapy is extensive.
  • Chemotherapy has a well-documented role in the curative and palliative treatment of patients with several types of cancer.
  • The use of chemotherapy is of utmost importance for the possibility of cure in certain tumour types.
  • In other tumours, chemotherapy increases the possibility of cure when added to local and regional treatments, particularly surgery.
  • In the instances of no possibility of cure, chemotherapy may to a variable extent improve both patient survival and well-being.
  • In Sweden chemotherapy is largely used in accordance with that documented in the scientific literature.
  • The extent of both over- and under-treatment seems to be limited but cannot be excluded at the individual patient level.
  • The literature-based knowledge is scientifically of lower quality in the most chemotherapy sensitive tumours than in tumours showing more limited sensitivity.
  • In those days, clinical treatment studies did not fulfil the current high quality requirements.
  • Small life-prolonging effects of chemotherapy are sometimes very well documented in large, high quality scientific studies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Technology Assessment, Biomedical
  • [MeSH-minor] Cost-Benefit Analysis. Decision Making. Drug Costs. Evidence-Based Medicine. Humans. Sweden

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11441927.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 17
  •  go-up   go-down


11. Okawa Y, Shimada T, Nagasaki E, Nozato A, Mizoroki F, Kobayashi M: [Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma]. Rinsho Ketsueki; 2006 Jul;47(7):650-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma].
  • We report a case of follicular lymphoma in which pulmonary cryptococcosis occurred with cladribine therapy.
  • He was diagnosed as having follicular lymphoma, grade 1, clinical stage IVA from a tongue tumor biopsy in January 2003.
  • A total of 6 courses of R-CHOP therapy was performed, but no clear effect was found.
  • A new cervical lesion appeared, so he was treated with a total of 2 courses of R-EPOCH therapy, and the effect was classed as stable disease.
  • We started cladribine therapy (0.09 mg/kg, seven days of continuous infusion) from February 2004, and complete remission was achieved after 4 courses of cladribine therapy.
  • In January 2005, an abnormal nodular shadow in the right S10 area was found on chest CT images which was diagnosed as pulmonary cryptococcosis by serum antigen and a trans-bronchial lung biopsy.
  • Afterward, the fifth course of cladribine therapy and local radiation therapy were performed against a relapse of lymphoma, but cryptococcosis did not reappear.
  • The prolonged bone marrow suppression after cladribine therapy was considered to be a severe adverse event.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cladribine / adverse effects. Cryptococcosis / etiology. Lung Diseases, Fungal / etiology. Lymphoma, Follicular / drug therapy. Opportunistic Infections
  • [MeSH-minor] Bone Marrow / drug effects. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cryptococcosis.
  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910576.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


12. Kornacker M, Kraemer A, Leo E, Ho AD: Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases. Ann Hematol; 2002 Feb;81(2):103-5
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases.
  • Sarcoidosis-lymphoma syndrome is a well-established syndrome where sarcoidosis is followed by the development of a lymphoproliferative disease such as non-Hodgkin's lymphoma (NHL).
  • Here we report two patients with NHL who developed sarcoidosis subsequent to the diagnosis of lymphoproliferative disease.
  • In both cases, chemotherapeutic treatment had already been initiated or was completed when sarcoidosis occurred.
  • In these patients, sarcoidosis may have been triggered by immunologic aberrations induced by antineoplastic therapy or as a consequence of an underlying immunologic disturbance associated with the lymphoma.
  • When a suspected relapse of lymphoma presents with signs and symptoms compatible with sarcoidosis, this rare immunologic disorder has to be ruled out by careful clinical and histopathologic analysis to prevent mistreatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lung Diseases / chemically induced. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Sarcoidosis / chemically induced
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Murine-Derived. Clarithromycin / therapeutic use. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Male. Prednisolone / administration & dosage. Prednisolone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Prednisone / therapeutic use. Rituximab. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11907791.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; H1250JIK0A / Clarithromycin; VB0R961HZT / Prednisone; CHOEP protocol; CHOP protocol
  •  go-up   go-down


13. Iguchi T, Yokoyama K, Mitsuishi M, Chen CK, Ikeda Y, Okamoto S: [Pulmonary tuberculosis and adenovirus-hemorrhagic cystitis after autologous peripheral blood stem cell transplantation for follicular lymphoma]. Rinsho Ketsueki; 2005 Sep;46(9):1049-54
MedlinePlus Health Information. consumer health - Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary tuberculosis and adenovirus-hemorrhagic cystitis after autologous peripheral blood stem cell transplantation for follicular lymphoma].
  • A 58-year-old man had a relapsed follicular lymphoma (Grade 2) and was treated with mitoxantrone, fludarabine and dexamethasone followed by rituximab, and achieved partial remission.
  • The patient then underwent high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT).
  • Three days after starting high-dose therapy, he developed a fever, and a chest X-ray revealed pneumonia in the right lower lung.
  • On day 43 he also developed hemorrhagic cystitis due to adenovirus type 11, and on day 49 positive CMV antigenemia was detected, which were treated supportively.
  • On day 75 he developed pneumonia probably due to Pneumocystis jirovecii, which was treated with sulfamethoxazole/trimethoprim.
  • The pulmonary tuberculosis resolved completely 4 months after starting the treatment, and the hemorrhagic cystitis and pneumocystis pneumonia resolved 1 month after the diagnosis.
  • [MeSH-major] Adenovirus Infections, Human / etiology. Cystitis / virology. Hemorrhage / etiology. Lymphoma, Follicular / therapy. Peripheral Blood Stem Cell Transplantation / adverse effects. Tuberculosis, Pulmonary / etiology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440763.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Farris AB 3rd, Kradin RL: Follicular localization of dendritic cells in a xanthomatous inflammatory tumor of lung associated with human herpes virus-8 infection. Virchows Arch; 2006 Dec;449(6):726-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular localization of dendritic cells in a xanthomatous inflammatory tumor of lung associated with human herpes virus-8 infection.
  • A 17-year-old man was treated with chemotherapy and radiation for nodular sclerosing Hodgkin lymphoma that presented as a left chest wall mass.
  • Ten years later, a left upper lobe lung tumor was identified.
  • The tumor resection demonstrated a 1.3-cm yellow lung nodule composed of epithelioid and spindled lipid-laden CD68+ and Factor XIIIa+ macrophages.
  • Distinct follicular structures with dendritic cells positive for CD1a, fascin, and ALK-1 and largely devoid of intracytoplasmic lipid were a distinguishing feature of the lesion.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Granuloma, Plasma Cell / pathology. Herpesvirus 8, Human / isolation & purification. Lung Neoplasms / pathology. Xanthomatosis / pathology
  • [MeSH-minor] Activin Receptors, Type II / analysis. Adolescent. Antigens, CD1 / analysis. Humans. Male

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2002 Jul;41(1):1-29 [12121233.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):276-81 [1309172.001]
  • [Cites] Am J Surg Pathol. 1991 Dec;15(12):1181-7 [1720931.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1089-91; author reply 1091-2 [12170101.001]
  • [Cites] Lab Invest. 2000 Jul;80(7):1121-6 [10908158.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):1065-8 [8092397.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):624-9 [11342774.001]
  • [Cites] Histopathology. 2005 Jun;46(6):604-13 [15910591.001]
  • [Cites] Chest. 1987 Oct;92 (4):756-7 [3652767.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;416(4):281-6 [2106746.001]
  • (PMID = 17106709.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / CD1a antigen; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


15. Graham BB, Mathisen DJ, Mark EJ, Takvorian RW: Primary pulmonary lymphoma. Ann Thorac Surg; 2005 Oct;80(4):1248-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary lymphoma.
  • BACKGROUND: Primary pulmonary lymphoma is a rare disease.
  • The clinical characteristics, methods of treatment, and outcomes are not well elucidated.
  • METHODS: A retrospective review of primary pulmonary lymphoma cases at a single institution from 1990 to 2002 was performed.
  • Fourteen patients had mucosa-associated lymphoid tissue (MALT) lymphoma, 2 had large cell transformation of sheet cells in MALT lymphoma, and 1 each had Hodgkin's disease and follicular lymphoma.
  • Computed tomography-guided biopsy was diagnostic in only two of eight attempts.
  • Treatment methods included observation only (n = 1), surgery only (n = 6), surgery plus chemotherapy (n = 8), surgery plus radiotherapy (n = 1), and surgery plus chemotherapy plus radiotherapy (n = 2).
  • Kaplan-Meier estimate of median time to disease recurrence or death was 6 years.
  • CONCLUSIONS: A wide range of treatments were used for patients with generally MALT lymphoma, resulting in good outcomes, and recurrent disease was well controlled.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Lymphoma / diagnosis. Lymphoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Hodgkin Disease / pathology. Hodgkin Disease / radiography. Hodgkin Disease / surgery. Humans. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiography. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Follicular / pathology. Lymphoma, Follicular / radiography. Lymphoma, Follicular / surgery. Male. Middle Aged. Neoplasm Staging / methods. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181848.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Valmorri L, Riccobon A, Ridolfi R: Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. J Clin Oncol; 2009 May 20;27(15_suppl):9042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment.
  • The combination of immunotherapies with standard treatments for cancer could represent a further chance for advanced melanoma patients.
  • In the literature, higher response rates than those normally obtained have been reported after second-line chemotherapy in patients with non small cell lung cancer pre-treated with vaccines and in patients with follicular B-cell lymphoma vaccinated with an anti-idiotype vaccine whilst in remission.
  • METHODS: From December 2002 to 2007, 24 pre-treated metastatic melanoma patients were vaccinated with mature DCs (mDCs) pulsed with autologous tumor lysate (ATL) and keyhole limpet hemocyanin (KLH) followed by a 5-day treatment with low-dose subcutaneous Interleukin-2.
  • All 13 responders had delayed-type hypersensitivity (DTH) positivity to KLH, of whom 10 also showed positivity to the lysate.
  • Eleven (45.8%) of the 24 patients underwent further lines of treatment (5 chemotherapy [CT], 3 surgery [S], 4 biotherapy, 2 radiotherapy [RT] and 4 biochemotherapy [BioCT]) after stopping vaccination (8 due to progression and 3, in SD, because all of their lysate had been used).
  • Of these 11 patients, 2 obtained CR (1 RT, 1 S), 5 PR (3 BioCT, 2 S) for an OR of 63.6%, 1 SD (BioCT) and 3 showed PD as the best response to subsequent therapies, with a median OS of 30 months (range 16-52).
  • Of the 3 SD patients who were forced to stop vaccine treatment, 1 had CR following RT and 2 progressed.
  • CONCLUSIONS: Metastatic melanoma responds poorly to standard therapy, in particular after first-line treatment.
  • Vaccination could enhance clinical response to subsequent third- or fourth-line therapies, thus prolonging overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kataoka T, Ishida Y, Kurokawa R, Takeshita S, Ohta K, Nishimura Y, Yokoyama M: [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab]. Nihon Kokyuki Gakkai Zasshi; 2003 Dec;41(12):899-904
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab].
  • Histopathological examination of the inguinal lymph nodes revealed follicular B-cell non-Hodgkin's lymphoma (NHL).
  • In spite of 9 cycles of chemotherapy (CHOP/COP), progression of the disease was seen.
  • Fever and dyspnea developed.
  • Transbronchial biopsy revealed pulmonary involvement of diffuse B-cell lymphoma.
  • Salvage chemotherapy (ESHAP, EPOCH) was not effective.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14727553.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


18. Azim HA, Elsedewy E, Azim HA Jr: Imatinib in the treatment of follicular dendritic sarcoma: a case report and review of literature. Onkologie; 2007 Jul;30(7):381-4
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib in the treatment of follicular dendritic sarcoma: a case report and review of literature.
  • Follicular dendritic cell sarcoma is a rare, malignant, non-lymphoid cell-derived tumor that originates from B-lymphoid follicles of nodal and extranodal sites.
  • Surgery and radiotherapy were considered the mainstay of treatment for localized disease.
  • As for the metastatic setting, classic lymphoma and sarcoma regimens were previously tested with dismal responses.
  • PATIENT AND METHODS: In this report, we examined imatinib in combination with gemcitabine and cisplatin for treating a male patient with metastatic follicular dendritic sarcoma to the liver and lung.
  • RESULTS: The patient achieved complete pathological remission confirmed by positron emission tomography (PET) scan after 8 cycles.
  • An imatinibbased combination could serve as a good therapeutic option for such cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dendritic Cells, Follicular. Head and Neck Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Sarcoma / secondary
  • [MeSH-minor] Benzamides. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Cisplatin / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Follow-Up Studies. Humans. Imatinib Mesylate. Lymphatic Metastasis / pathology. Male. Middle Aged. Positron-Emission Tomography. Proto-Oncogene Proteins c-kit / analysis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17596748.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 0W860991D6 / Deoxycytidine; 8A1O1M485B / Imatinib Mesylate; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 20
  •  go-up   go-down


19. Tian XL, Feng RE, Shi JH, Duan MH, Wang JL, Liu HR, Cai BQ, Gao JM, Xu WB, Zhu YJ: [Primary pulmonary lymphoma: analysis of 18 cases]. Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jun;31(6):401-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary pulmonary lymphoma: analysis of 18 cases].
  • OBJECTIVE: To study the clinical characteristics, pathology, diagnosis and treatment of primary pulmonary lymphoma.
  • METHODS: Eighteen cases of primary pulmonary lymphoma diagnosed from Jan 1989 to Feb 2007 were retrospectively analyzed.
  • Fifteen cases were diagnosed by surgical lung biopsy; 1 by percutaneous needle lung biopsy (1/6), 1 by percutaneous needle lung biopsy and bronchoscopic examination at the same time, the other 1 by bronchoscopic examination (1/10).
  • Histological diagnosis showed that 2 cases were Hodgkin lymphoma, 9 mucosa-associated lymphoid tissue lymphoma, 1 follicular lymphoma, 2 diffuse large B cell lymphoma 2 anaplastic large cell lymphoma, 2 non-Hodgkin lymphoma whichcould not be classified because the slides were from other hospitals.
  • Treatment modalities included surgical resection, radiotherapy and chemotherapy.
  • Median follow-up time was 11 months (10 d to 205 mon).
  • CONCLUSIONS: The clinical manifestations of primary pulmonary lymphoma are nonspecific.
  • Surgical lung biopsy is necessary for early diagnosis.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lymphoma / diagnosis. Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031796.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Chorianopoulos D, Samitas K, Vittorakis S, Kiriazi V, Rondoyianni D, Tsaousis G, Skoutelis A: Extranodal natural killer/T-cell lymphoma, nasal-type. Skinmed; 2010 Jan-Feb;8(1):56-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal natural killer/T-cell lymphoma, nasal-type.
  • On admission, physical examination revealed a well-orientated man in mild distress, with inspiratory rhonchi at the lower part of the left lung and scattered erythematous nodules of variable size, some of which were ulcerated.
  • The differential diagnosis, considering the evidence described, included granulomatous or infectious diseases, angiocentric lymphoproliferative lesions, and lymphomas.
  • Biopsy of a skin lesion showed lymphoproliferative infiltration of the dermis with a follicular and angiocentric growth pattern and regional epidermal necrosis.
  • The morphology and the immunophenotype were consistent with natural killer/T-cell lymphoma, nasal-type.
  • Nasal involvement must be first excluded to proceed to the diagnosis of nasal-type natural killer-cell lymphoma.
  • Thus, the authors were led to the diagnosis of extranodal extranasal natural killer/T-cell lymphoma, nasal-type, CD56-positive, Ep stein-Barr virus-negative, TCR-negative.
  • The patient received combination chemotherapy and completed 4 cycles of cyclophosphamide, doxorubicin vincristine, and prednisone every 14 days for 2 months.
  • Skin lesions improved, and there was no fever soon after the initiation of therapy.
  • The patient had receive systemic salvage chemotherapy and intrathecal infusions of methotrexate.
  • Although the lung lesions had diminished at that time, the patient develope paraplegia, his clinical course rapidly deteriorated, and he eventually died.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20839428.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Yi XH, Zhou XY, Zhang TM, Zhou CC, Su B, Zhang Y: [The value of detection of gene rearrangement of immunoglobulin heavy chain and immunohistochemistry in pulmonary mucosa-associated lymphoid tissue type lymphoma]. Zhonghua Jie He He Hu Xi Za Zhi; 2005 Oct;28(10):704-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of detection of gene rearrangement of immunoglobulin heavy chain and immunohistochemistry in pulmonary mucosa-associated lymphoid tissue type lymphoma].
  • OBJECTIVE: To investigate the features of gene rearrangement of immunoglobulin heavy chain (IgH) and immunophenotypes of pulmonary mucosa-associated lymphoid tissue type lymphoma (MALTLoma).
  • RESULTS: The patients included 9 cases confirmed by open or video-assisted thoracoscopic lung biopsy and 3 cases by needle lung biopsy.
  • Histopathologically, the tumors were composed of a spectrum of cell types that included mainly centrocyte-like cells and small lymphocytes.
  • Lymphoepithelial lesions were identified in 12 cases, reactive colliculus lymphaticus in 11 cases, follicular colonization in 10 cases, vascular infiltration in 9 cases, and pleura involvement in 4 cases.
  • The detection of TCRgamma1 and TCRgamma2 was negative in 7 cases.
  • Chemotherapy alone was administered in 3 patients, surgery alone was performed in 8 patients, and chemotherapy after operation was carried out in 6 patients.
  • Eight of them were alive and stable, one experienced relapse and two died of the disease within 11 years and 12 years after diagnosis respectively.
  • PCR detection of IgH gene rearrangement would be helpful in differential diagnosis from benign lymphoplasia of the lung.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16255957.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


22. Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA: Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma; 2003 Jun;44(6):1027-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.
  • In prior studies, PDX exhibited enhanced efficacy over methotrexate (MTX) in lung and breast carcinoma xenografts.
  • Because MTX is active in the treatment of aggressive non-Hodgkin's lymphoma (NHL), we compared the efficacy of PDX and MTX against five lymphoma cell lines: RL (transformed follicular lymphoma), HT, SKI-DLBCL-1 (diffuse large B cell), Raji (Burkitt's), and Hs445 (Hodgkin's disease).
  • Almost 90% of HT lymphomas treated with PDX completely regressed, whereas, those treated with MTX treatment had only modest growth delays.
  • In two other xenografts, tumor bearing mice had complete regression rates of 56% (RL) and 30% (SKI-DLBCL-1) after PDX therapy.
  • No regressions and only minor growth inhibition was noted after MTX therapy.
  • [MeSH-major] Aminopterin / analogs & derivatives. Aminopterin / toxicity. Cell Survival / drug effects. Lymphoma / drug therapy. Lymphoma / pathology. Methotrexate / toxicity
  • [MeSH-minor] Animals. Apoptosis / drug effects. Folic Acid Antagonists / therapeutic use. Folic Acid Antagonists / toxicity. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Transplantation, Heterologous. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12854905.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-0172; United States / NCI NIH HHS / CA / CA-09207-24
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 10-propargyl-10-deazaaminopterin; 0 / Folic Acid Antagonists; JYB41CTM2Q / Aminopterin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


23. Mozek C, Novotny J, Dührsen U, Metz KA: [Lymphadenopathy in the groin. Unusual etiology in a 65-year-old patient]. Internist (Berl); 2004 Jan;45(1):90-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 65 year old female patient was admitted to our hospital with unspecific symptoms and a lump in the right groin which raised suspicion of a malignant lymphoma.
  • Histologically a follicular dendritic reticular cell tumor was found.
  • Because there are aggressive forms of this tumor and no established standard therapy, we decided to treat her with surgery followed by a combined radio- and chemotherapy.
  • Despite this treatment 16 months after the first diagnosis a relapse occurred with a metastasis of the follicular dendritic cell tumor in the lung.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Groin. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2002 Jul;41(1):1-29 [12121233.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):50-8 [11796841.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):562-72 [2420185.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):944-55 [8712294.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):144-54 [9606805.001]
  • [Cites] Arch Pathol Lab Med. 2000 Nov;124(11):1693-6 [11079028.001]
  • [Cites] Am J Otolaryngol. 2002 Mar-Apr;23(2):93-8 [11893977.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):664-72 [10931467.001]
  • [Cites] Ann Surg. 1987 Apr;205(4):349-59 [3566372.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):294-313 [9010103.001]
  • (PMID = 14735246.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Gupta S, Mahipal A: Fatal pulmonary toxicity after a single dose of cyclophosphamide. Pharmacotherapy; 2007 Apr;27(4):616-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclophosphamide-induced pulmonary toxicity is extremely rare and often difficult to recognize because of presence of confounding factors, including use of other cytotoxic drugs, radiation pneumonitis, oxygen toxicity, pulmonary infections, and malignancies.
  • The lung toxicity caused by cyclophosphamide is accelerated when cyclophosphamide is combined with amiodarone, an antiarrhythmic agent also capable of lung toxicity.
  • We describe a patient with non-Hodgkin's lymphoma who developed fatal pulmonary toxicity after a single dose of cyclophosphamide in the setting of long-term amiodarone use.
  • [MeSH-major] Cyclophosphamide / adverse effects. Lung / drug effects. Lung Diseases / chemically induced
  • [MeSH-minor] Aged. Amiodarone / adverse effects. Amiodarone / therapeutic use. Anti-Arrhythmia Agents / adverse effects. Anti-Arrhythmia Agents / therapeutic use. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Dose-Response Relationship, Drug. Fatal Outcome. Female. Humans. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / physiopathology

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381391.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; N3RQ532IUT / Amiodarone
  •  go-up   go-down


25. Cheson BD, Rummel MJ: Bendamustine: rebirth of an old drug. J Clin Oncol; 2009 Mar 20;27(9):1492-501
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bendamustine: rebirth of an old drug.
  • Bendamustine is a unique cytotoxic agent with structural similarities to alkylating agents and antimetabolites, but which is non-cross-resistant with alkylating agents and other drugs in vitro and in the clinic.
  • Early clinical studies conducted in the German Democratic Republic more than 30 years ago suggested promising activity in indolent non-Hodgkin's lymphoma (NHL).
  • Two North American trials reported responses in more than 70% of patients with chemotherapy- and rituximab-refractory disease, suggesting that bendamustine may be the most effective drug available for this patient population.
  • Response rates of 90% to 92%, with complete remission in 55% to 60%, have been reported in patients with follicular and mantle-cell lymphoma with the combination of bendamustine and rituximab.
  • Bendamustine is approved in Germany for the treatment of patients with indolent NHL, CLL, and multiple myeloma.
  • Activity has also been noted in patients with breast cancer and small-cell lung cancer [corrected].
  • Questions related to the optimization of bendamustine therapy, including dose and schedule, role relative to other available agents, and management of toxicities, are being investigated.
  • However, the availability of bendamustine provides another effective treatment option for patients with lymphoid malignancies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Nitrogen Mustard Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Bendamustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 Jun 10;27(17):2892
  • (PMID = 19224851.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride
  • [Number-of-references] 66
  •  go-up   go-down


26. Gow KW, Lensing S, Hill DA, Krasin MJ, McCarville MB, Rai SN, Zacher M, Spunt SL, Strickland DK, Hudson MM: Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature. J Pediatr Surg; 2003 Nov;38(11):1574-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature.
  • METHODS: The authors reviewed the medical records of 8 children with PTM and 17 children with STM referred to St Jude Children's Research Hospital between February 1962 and February 2002 for evaluation and treatment of malignant thyroid carcinoma.
  • Seven patients had papillary carcinoma, and 1 patient had follicular carcinoma.
  • Three of the 8 (37.5%) had metastatic disease involving regional lymph nodes; 2 patients (25.0%) had lung metastases.
  • All 8 patients remain alive a median of 22.6 years after diagnosis (range, 0.7 to 30.5 years); 1 continues to receive radioactive iodine (I 131) ablation for persistent disease.
  • Seventeen patients had thyroid carcinoma as a second malignant neoplasm after treatment for acute lymphoblastic leukemia (n = 6), Hodgkin's disease (n = 5), central nervous system tumor (n = 2), Wilms' tumor (n = 1), retinoblastoma (n = 1), non-Hodgkin's lymphoma (n = 1), or neuroblastoma (n = 1).
  • Patients with secondary thyroid carcinoma presented at a median age of 21.5 years (range, 15.3 to 42.6 years), a median of 16.2 years (range, 0.9 to 29.2 years) after diagnosis of the primary cancer.
  • Twelve of the 17 patients (70.6%) had received radiation to the thyroid gland during therapy for the primary cancer.
  • At the time of this report, all 17 patients are alive and in continue to be free of disease.
  • CONCLUSIONS: Pediatric thyroid carcinoma is uncommon and responds well to current therapy.
  • [MeSH-major] Adenocarcinoma, Follicular / epidemiology. Carcinoma, Papillary / epidemiology. Neoplasms, Second Primary / epidemiology. Thyroid Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Cohort Studies. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Neoplasms / drug therapy. Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / epidemiology. Retrospective Studies. Tennessee / epidemiology. Thyroidectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614703.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Number-of-references] 49
  •  go-up   go-down


27. Anderson P, Höglund M, Rödjer S: Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies. Am J Hematol; 2003 May;73(1):54-8
Hazardous Substances Data Bank. Carbon monoxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies.
  • Several side effects of interferon-alpha-2b (IFN-alpha) therapy have been described.
  • The four patients we describe all developed respiratory disorders while being treated with IFN-alpha for hematological malignancies.
  • Also, in addition to our review of the literature, we discuss the possible mechanisms involved in development of lung symptoms.
  • The decrease in diffusion capacity and the clinical symptoms were completely reversible in three of the patients, either spontaneously after the withdrawal of IFN-alpha or after treatment with corticosteroids.
  • When pulmonary symptoms are evaluated during IFN-alpha therapy, spirometry, including estimation of carbon monoxide diffusion capacity, high-resolution computerized tomography, and ultracardiography should be used.
  • [MeSH-major] Hematologic Neoplasms / drug therapy. Interferon-alpha / adverse effects. Lung Diseases / chemically induced
  • [MeSH-minor] Adult. Aged. Autoimmunity. Carbon Monoxide / metabolism. Female. Humans. Immunity, Cellular. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Lung Diseases, Interstitial / immunology. Lymphoma, Follicular / drug therapy. Male. Primary Myelofibrosis / drug therapy. Prognosis. Spirometry

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12701122.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 7U1EE4V452 / Carbon Monoxide
  •  go-up   go-down


28. Ishizawa S, Slovak ML, Popplewell L, Bedell V, Wrede JE, Carter NH, Snyder DS, Arber DA: High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities. Leukemia; 2003 Jun;17(6):1091-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the frequency and cytogenetic and immunophenotypic features of therapy-related, precursor B-cell acute lymphoblastic leukemia (ALL), 152 cases of immature B-cell ALL were reviewed.
  • These were compared to the frequency of therapy-related acute myeloid leukemia (t-AML) during the same time period.
  • Eight ALL cases with a prior diagnosis of malignancy were identified, including six (4.0%) with prior therapy considered to be therapy-related ALL (t-ALL).
  • The t-ALL cases followed treatment for breast carcinoma (two cases), lung carcinoma (two cases), lymphocyte predominance Hodgkin's disease and follicular lymphoma with a latency period of 13 months to 8 years.
  • During the same time period, 4.9% of all AML cases were considered t-AML.
  • Despite the similar frequency in therapy-related disease among ALL and AML cases, there were differences in the frequency of the diseases and t-ALL represented 12% of all therapy-related leukemias.
  • However, t-ALL represented 46% of all 11q23-positive therapy-related leukemias.
  • The immunogenetic features of t-ALL appear distinct and may aid in identifying more cases of this disease type in the future.
  • [MeSH-major] Burkitt Lymphoma / etiology. Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Leukemia, Myeloid / etiology. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Antigens, CD / immunology. Antineoplastic Agents / therapeutic use. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Neoplasms / drug therapy. Neoplasms / radiotherapy. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12764373.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 30206; United States / NCI NIH HHS / CA / CA 33572
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antineoplastic Agents
  •  go-up   go-down


29. Wolach O, Bairey O, Lahav M: Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore); 2010 Sep;89(5):308-18
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
  • Rituximab is a chimeric monoclonal antibody against CD20 that is used mainly for the treatment of CD20-positive lymphoma.
  • Recently, its use has been expanded to include treatment of other nonmalignant diseases such as rheumatologic diseases and autoimmune cytopenia.
  • Most investigators define LON as grade III-IV neutropenia occurring 3-4 weeks after the last treatment with rituximab, in the absence of an alternative explanation for the neutropenia.We report 6 cases of LON identified in our institution.
  • Four patients were treated for diffuse large B-cell lymphoma, and 2 patients for follicular lymphoma.
  • One patient presented with LON and concomitant subacute pulmonary disease that was attributed to rituximab therapy.In addition to our own case series we present a systematic review of the literature, which we performed to compile data to describe better the syndrome of LON.
  • Data regarding populations at risk are not consistent, and in some instances are conflicting.Patients considered at increased risk of LON include patients after autologous stem cell transplantation, patients treated for acquired immunodeficiency syndrome (AIDS)-related lymphoma, and patients treated with purine analogues.
  • Patients who received previous cytotoxic treatment as well as those treated with more intensive chemotherapy or with chemotherapy in combination with radiotherapy are also considered to be at risk of LON.
  • A recent study correlated specific polymorphism in the immunoglobulin G Fc receptor FCγRIIIa 158 V/F with increased rates of LON.The clinical significance of LON is important because it may affect treatment strategies.
  • Re-treatment with rituximab after LON may result in recurrent episodes, but the implications and risks are uncertain at the present time.
  • The role of growth factors once LON appears is ill defined, and the decision to use them should be made on a case-by-case basis.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / adverse effects. Neoplasms / drug therapy. Neutropenia / chemically induced
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Lung Diseases / chemically induced. Lung Diseases / epidemiology. Male. Middle Aged. Risk Factors. Rituximab. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20827108.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


30. Disel U, Paydas S, Yavuz S, Karakoc E: Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab. Chemotherapy; 2010;56(2):89-93
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fludarabine is a nucleoside analogue used in the treatment of low-grade lymphoproliferative disorders and in conditioning regimens of non-myeloablative allogeneic stem cell transplantation.
  • This is a relatively safe drug for clinical use but may cause side effects, some of which may be life-threatening.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lung Diseases / chemically induced
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Humans. Lymphoma, Follicular / drug therapy. Male. Middle Aged. Rituximab. Severity of Illness Index. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 S. Karger AG, Basel.
  • (PMID = 20357439.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


31. Herishanu Y, Polliack A, Leider-Trejo L, Grieff Y, Metser U, Naparstek E: Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma; 2006 Mar;6(5):407-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rituximab, a chimeric anti-CD20 monoclonal antibody, is commonly being used to treat indolent and aggressive B-cell non-Hodgkin's lymphoma.
  • Rituximab is considered a relatively safe drug, but recently, severe and fatal adverse effects related to this drug have been reported.
  • In this regard, we report an 80-year-old patient with follicular grade 3 non-Hodgkin's lymphoma who developed a fatal interstitial pneumonitis related to treatment with a rituximab/CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) regimen.
  • The pneumonitis was diagnosed on a routine midtreatment positron emission tomography/computed tomography scan when the patient was almost asymptomatic.
  • Pulmonary deterioration occurred as the treatment with rituximab/CHOP was continued.
  • In this article, we also review the literature on rituximab-associated pneumonitis, and we discuss the differential diagnosis with cyclophosphamide-induced lung injury.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lung Diseases, Interstitial / chemically induced. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Biopsy, Needle. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Disease Progression. Dose-Response Relationship, Drug. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Drug Administration Schedule. Fatal Outcome. Humans. Immunohistochemistry. Male. Neoplasm Staging. Prednisolone / adverse effects. Prednisolone / therapeutic use. Radiography, Thoracic. Risk Assessment. Rituximab. Tomography, X-Ray Computed. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640819.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


32. Wiseman GA, Leigh BR, Dunn WL, Stabin MG, White CA: Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy. Cancer Biother Radiopharm; 2003 Apr;18(2):253-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Zevalin (ibritumomab tiuxetan) radioimmunotherapy is a novel treatment for non-Hodgkin's lymphoma (NHL).
  • In a 143-patient, Phase III, randomized study, the Zevalin regimen produced a significantly higher overall response rate than rituximab for relapsed or refractory, low-grade, follicular, or transformed NHL (80% versus 56%, p = 0.02).
  • Fifteen patients from the Zevalin arm of this study were randomly selected for additional radiation dosimetry. (90)Y residence times were calculated from (111)In image analysis data.
  • MIRDOSE3.1 radiation absorbed dose estimates to normal tissues were highest for spleen, testes, and liver, with considerably lower doses reaching heart, lung, intestines, red marrow, and kidneys.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Dose-Response Relationship, Radiation. Lymphoma, Non-Hodgkin / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. Male. Prospective Studies. Rituximab. Salvage Therapy. Tissue Distribution. Tomography, Emission-Computed. Treatment Outcome. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12804052.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


33. Van Den Neste E, Michaux L, Layios N, Costantini S, Francart J, Lambert C, Sonet A, André M, Robert A, Ferrant A: High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol; 2004 Jun;83(6):356-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnoses were chronic lymphocytic leukemia (CLL) in 15, Waldenström's macroglobulinemia in 4, mantle cell lymphoma in 6, follicular non-Hodgkin's lymphoma (NHL) in 10, and other low-grade NHL in 3 patients.
  • In 12 (32%) patients, autoimmune manifestations developed requiring treatment in most of them.
  • Second cancers arose in five (13%) patients (myelodysplastic syndrome/acute myelocytic leukemia in three, lung cancer in two).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoproliferative Disorders / complications. Lymphoproliferative Disorders / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15024607.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


34. Gupta S, Jain A, Fanning TV, Couriel DR, Jimenez CA, Eapen GA: An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: a case report. BMC Cancer; 2006;6:87
Hazardous Substances Data Bank. THIABENDAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hematopoietic stem cell transplantation is being increasingly used in cancer therapy.
  • Therapy with parenteral ivermectin and thiabendazole was initiated but the patient deteriorated and died of respiratory failure and septic shock.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hemorrhage / etiology. Lung Diseases, Parasitic / complications. Postoperative Complications / etiology. Strongyloides stercoralis. Strongyloidiasis / complications
  • [MeSH-minor] Animals. Anti-Infective Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fatal Outcome. Humans. Immunocompromised Host. Ivermectin / therapeutic use. Klebsiella Infections / complications. Klebsiella Infections / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / surgery. Male. Middle Aged. Pulmonary Alveoli / parasitology. Pulmonary Alveoli / pathology. Sepsis / complications. Sepsis / drug therapy. Shock, Septic / etiology. Thiabendazole / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Apr 1;100(7):1531-6 [15042689.001]
  • [Cites] CMAJ. 2004 Aug 31;171(5):479-84 [15337730.001]
  • [Cites] Rev Infect Dis. 1981 May-Jun;3(3):397-407 [7025145.001]
  • [Cites] Am J Clin Pathol. 1988 Mar;89(3):391-4 [3348175.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(1):115-7 [12815488.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1994 May-Jun;88(3):344-5 [7974685.001]
  • [Cites] Int J Parasitol. 1995 Apr;25(4):411-20 [7635616.001]
  • [Cites] J Clin Gastroenterol. 2005 Mar;39(3):203-11 [15718861.001]
  • [Cites] Rev Infect Dis. 1989 Sep-Oct;11(5):755-67 [2682948.001]
  • (PMID = 16603072.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 70288-86-7 / Ivermectin; N1Q45E87DT / Thiabendazole
  • [Other-IDs] NLM/ PMC1479356
  •  go-up   go-down


35. Preisz K, Horváth A, Sárdy M, Somlai B, Hársing J, Amagai M, Hashimoto T, Nagata Y, Fekete S, Kárpáti S: Exacerbation of paraneoplastic pemphigus by cyclophosphamide treatment: detection of novel autoantigens and bronchial autoantibodies. Br J Dermatol; 2004 May;150(5):1018-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exacerbation of paraneoplastic pemphigus by cyclophosphamide treatment: detection of novel autoantigens and bronchial autoantibodies.
  • A 48-year-old woman with a follicular, grade III, B-cell non-Hodgkin lymphoma developed clinical, immunopathological and histological features of paraneoplastic pemphigus.
  • Although the skin and oral mucosal disease went into remission with high-dose steroid and intravenous immunoglobulin therapy, the severe alveolitis led to death.
  • Serum IgG and IgA strongly stained rat bronchial epithelium, corresponding to autoantibodies possibly involved in the pathomechanism of the severe lung disease.
  • In this case, which was characterized by a mixed IgA/IgG antibody panel displaying known and unique antigenicity, the serious episodes of paraneoplastic pemphigus flared after cyclophosphamide treatment.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Cyclophosphamide / adverse effects. Drug Eruptions / etiology. Paraneoplastic Syndromes / chemically induced. Pemphigus / chemically induced

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15149520.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Autoantibodies; 0 / Autoantigens; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


36. Einsele H: Bortezomib. Recent Results Cancer Res; 2010;184:173-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ubiquitin-mediated degradation of proteins in numerous cellular processes, such as turnover and quality control of proteins, cell cycle and apoptosis, transcription and cell signaling, immune response and antigen presentation, and inflammation and development makes the ubiquitin-proteosome systems a very interesting target for various therapeutic interventions.
  • The possibility that proteosome inhibitors could be drug candidates was considered after studies showed that they induced apoptosis in leukemic cell lines.
  • The first proteasome inhibitor in clinical application, Bortezomib showed activity in non small cell lung and androgen-independent prostate carcinoma, as well as MM and mantle cell and follicular non-Hodgkin's lymphoma.
  • It is now lincensed for the treatment of newly diagnosed as well as relapsed/progressive MM and has had a major impact on the improvement in the treatment of MM in the last few years.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Multiple Myeloma / drug therapy. Protease Inhibitors / therapeutic use. Proteasome Inhibitors. Pyrazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20072838.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Number-of-references] 154
  •  go-up   go-down


37. Roccaro AM, Vacca A, Ribatti D: Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov; 2006 Nov;1(3):397-403
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib in the treatment of cancer.
  • Multiple myeloma is the prototype of cancer where bortezomib has shown marked in vitro activity, which was followed by rapid translation to phase I, II and III clinical trials, and resulted in accelerated approval by the FDA for the treatment of patients with relapsed refractory disease.
  • Different clinical trials are currently ongoing in multiple myeloma as well as in many others haematologic and solid tumors (mantle cell and follicular non-Hodgkin's lymphoma; peripheral T-cell lymphoma; Waldenström's macroglobulinemia, chronic lymphocytic leukemia; head and neck / gastroesophageal junction / stomach /colo-rectal / prostate / non-small cell lung cancer).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Neoplasms / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Animals. Apoptosis / drug effects. Bortezomib. Clinical Trials as Topic. Humans. Patents as Topic. Proteasome Inhibitors. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18221049.001).
  • [ISSN] 1574-8928
  • [Journal-full-title] Recent patents on anti-cancer drug discovery
  • [ISO-abbreviation] Recent Pat Anticancer Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Number-of-references] 53
  •  go-up   go-down






Advertisement